 William Golden
Concepts (185)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicaid | 10 | 2025 | 263 | 2.320 |
Why?
| | Quality of Health Care | 9 | 2008 | 187 | 1.490 |
Why?
| | Patient-Centered Care | 3 | 2025 | 139 | 1.400 |
Why?
| | Arkansas | 28 | 2025 | 2016 | 1.190 |
Why?
| | Quality Indicators, Health Care | 5 | 2008 | 91 | 0.830 |
Why?
| | Medicare | 5 | 2014 | 273 | 0.780 |
Why?
| | Anti-Bacterial Agents | 2 | 2025 | 796 | 0.760 |
Why?
| | Delivery of Health Care | 5 | 2008 | 318 | 0.650 |
Why?
| | Practice Guidelines as Topic | 7 | 2008 | 494 | 0.530 |
Why?
| | Reimbursement Mechanisms | 3 | 2014 | 24 | 0.500 |
Why?
| | United States | 13 | 2025 | 5168 | 0.490 |
Why?
| | Drug Prescriptions | 2 | 2006 | 104 | 0.450 |
Why?
| | Humans | 42 | 2025 | 52114 | 0.450 |
Why?
| | Reimbursement, Incentive | 2 | 2013 | 12 | 0.440 |
Why?
| | Pregnancy Complications | 2 | 2021 | 401 | 0.430 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2014 | 52 | 0.410 |
Why?
| | Health Policy | 1 | 2014 | 160 | 0.390 |
Why?
| | Episode of Care | 1 | 2012 | 4 | 0.380 |
Why?
| | Cesarean Section | 1 | 2013 | 183 | 0.370 |
Why?
| | Appointments and Schedules | 1 | 2012 | 26 | 0.370 |
Why?
| | Anti-Inflammatory Agents | 2 | 2004 | 166 | 0.370 |
Why?
| | Hypertension | 2 | 2007 | 565 | 0.360 |
Why?
| | Quality Assurance, Health Care | 1 | 2012 | 147 | 0.350 |
Why?
| | Adolescent Health Services | 1 | 2011 | 6 | 0.350 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 3 | 2006 | 82 | 0.350 |
Why?
| | Asthma | 3 | 2004 | 314 | 0.340 |
Why?
| | Child Health Services | 1 | 2011 | 78 | 0.320 |
Why?
| | Drug Utilization Review | 1 | 2009 | 22 | 0.310 |
Why?
| | Efficiency, Organizational | 2 | 2015 | 41 | 0.300 |
Why?
| | Child Behavior Disorders | 1 | 2009 | 77 | 0.300 |
Why?
| | Primary Health Care | 1 | 2012 | 376 | 0.290 |
Why?
| | Mental Health Services | 1 | 2011 | 210 | 0.280 |
Why?
| | Efficiency | 1 | 2008 | 32 | 0.280 |
Why?
| | Chemoprevention | 2 | 2006 | 19 | 0.280 |
Why?
| | Total Quality Management | 1 | 2008 | 23 | 0.280 |
Why?
| | Benchmarking | 1 | 2008 | 64 | 0.280 |
Why?
| | Health Services Accessibility | 1 | 2012 | 438 | 0.270 |
Why?
| | Sociology, Medical | 1 | 2007 | 3 | 0.270 |
Why?
| | Antipsychotic Agents | 1 | 2009 | 235 | 0.270 |
Why?
| | Insurance, Pharmaceutical Services | 2 | 2006 | 25 | 0.260 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 270 | 0.260 |
Why?
| | Polypharmacy | 1 | 2006 | 15 | 0.250 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 44 | 0.250 |
Why?
| | Bipolar Disorder | 1 | 2008 | 199 | 0.250 |
Why?
| | Risk Factors | 7 | 2013 | 3922 | 0.250 |
Why?
| | Mass Screening | 3 | 2005 | 356 | 0.250 |
Why?
| | Community-Acquired Infections | 2 | 2003 | 42 | 0.240 |
Why?
| | Pediatrics | 1 | 2009 | 291 | 0.240 |
Why?
| | Thromboembolism | 1 | 2006 | 49 | 0.240 |
Why?
| | Patient Compliance | 1 | 2007 | 229 | 0.240 |
Why?
| | Pharyngitis | 1 | 2006 | 19 | 0.240 |
Why?
| | Diabetes Complications | 1 | 2006 | 124 | 0.240 |
Why?
| | Chlamydia Infections | 2 | 2005 | 75 | 0.230 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2007 | 179 | 0.230 |
Why?
| | Venous Thrombosis | 1 | 2006 | 90 | 0.230 |
Why?
| | Bacterial Infections | 1 | 2006 | 96 | 0.230 |
Why?
| | Benzodiazepines | 1 | 2005 | 71 | 0.230 |
Why?
| | Nursing Homes | 2 | 2002 | 108 | 0.230 |
Why?
| | Respiratory Tract Infections | 1 | 2006 | 81 | 0.230 |
Why?
| | Anti-Infective Agents | 1 | 2006 | 106 | 0.230 |
Why?
| | Physicians | 1 | 2008 | 235 | 0.220 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2005 | 33 | 0.220 |
Why?
| | Hemophilia B | 1 | 2004 | 5 | 0.220 |
Why?
| | Telemedicine | 1 | 2011 | 492 | 0.220 |
Why?
| | Vaginal Smears | 1 | 2004 | 28 | 0.220 |
Why?
| | Diagnostic Errors | 1 | 2004 | 69 | 0.220 |
Why?
| | Hemophilia A | 1 | 2004 | 26 | 0.210 |
Why?
| | Blood Pressure | 1 | 2006 | 535 | 0.210 |
Why?
| | Trust | 1 | 2004 | 60 | 0.210 |
Why?
| | Anemia, Sickle Cell | 1 | 2004 | 101 | 0.200 |
Why?
| | Renal Dialysis | 1 | 2005 | 190 | 0.200 |
Why?
| | Referral and Consultation | 1 | 2005 | 288 | 0.200 |
Why?
| | Anxiety | 1 | 2005 | 301 | 0.200 |
Why?
| | Government Regulation | 1 | 2002 | 14 | 0.200 |
Why?
| | Education, Medical, Continuing | 1 | 2003 | 72 | 0.190 |
Why?
| | Attitude to Health | 1 | 2004 | 191 | 0.190 |
Why?
| | Information Services | 1 | 2002 | 13 | 0.190 |
Why?
| | Medical Audit | 1 | 2002 | 20 | 0.190 |
Why?
| | Pneumonia | 1 | 2003 | 123 | 0.180 |
Why?
| | Ambulatory Care | 1 | 2003 | 239 | 0.180 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2004 | 299 | 0.170 |
Why?
| | Prenatal Care | 1 | 2002 | 110 | 0.170 |
Why?
| | Child | 6 | 2011 | 7147 | 0.170 |
Why?
| | Antibodies, Viral | 1 | 2021 | 110 | 0.170 |
Why?
| | Interleukin-1beta | 1 | 2021 | 87 | 0.160 |
Why?
| | Clinical Competence | 2 | 2008 | 396 | 0.160 |
Why?
| | Program Development | 2 | 2012 | 164 | 0.150 |
Why?
| | Patient Education as Topic | 3 | 2007 | 318 | 0.140 |
Why?
| | Pregnancy | 4 | 2021 | 2658 | 0.130 |
Why?
| | Inflammation | 1 | 2021 | 641 | 0.130 |
Why?
| | Blood Specimen Collection | 1 | 2015 | 35 | 0.110 |
Why?
| | Neonatal Screening | 1 | 2015 | 49 | 0.110 |
Why?
| | Tendinopathy | 1 | 2014 | 5 | 0.110 |
Why?
| | Shoulder Pain | 1 | 2014 | 9 | 0.110 |
Why?
| | Knee | 1 | 2014 | 25 | 0.110 |
Why?
| | Guideline Adherence | 2 | 2008 | 141 | 0.110 |
Why?
| | Federal Government | 1 | 2014 | 4 | 0.110 |
Why?
| | Uncompensated Care | 1 | 2014 | 4 | 0.110 |
Why?
| | Economics, Hospital | 1 | 2014 | 11 | 0.110 |
Why?
| | Female | 9 | 2021 | 28055 | 0.110 |
Why?
| | Financing, Government | 1 | 2014 | 23 | 0.110 |
Why?
| | State Government | 1 | 2014 | 46 | 0.110 |
Why?
| | Antibiotic Prophylaxis | 2 | 2005 | 61 | 0.100 |
Why?
| | Adrenergic beta-Agonists | 2 | 2004 | 42 | 0.100 |
Why?
| | Quality Improvement | 1 | 2015 | 223 | 0.100 |
Why?
| | Adrenal Cortex Hormones | 2 | 2004 | 114 | 0.090 |
Why?
| | Poverty | 1 | 2014 | 220 | 0.090 |
Why?
| | Adolescent | 3 | 2011 | 6681 | 0.090 |
Why?
| | Infant, Newborn | 4 | 2015 | 2859 | 0.090 |
Why?
| | Risk Assessment | 2 | 2006 | 1339 | 0.090 |
Why?
| | Child, Preschool | 3 | 2021 | 4001 | 0.090 |
Why?
| | Neonatology | 1 | 2011 | 15 | 0.090 |
Why?
| | Consultants | 1 | 2011 | 5 | 0.090 |
Why?
| | Certification | 1 | 2011 | 50 | 0.090 |
Why?
| | Prevalence | 1 | 2013 | 1013 | 0.080 |
Why?
| | Premature Birth | 1 | 2011 | 150 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 1518 | 0.070 |
Why?
| | Physician's Role | 1 | 2007 | 50 | 0.070 |
Why?
| | Organizational Culture | 1 | 2007 | 44 | 0.070 |
Why?
| | Aged, 80 and over | 2 | 2006 | 3382 | 0.070 |
Why?
| | Drug Monitoring | 1 | 2007 | 82 | 0.070 |
Why?
| | Infant | 2 | 2006 | 3660 | 0.060 |
Why?
| | Psychiatry | 1 | 2008 | 99 | 0.060 |
Why?
| | Drug Incompatibility | 1 | 2006 | 2 | 0.060 |
Why?
| | Methylphenidate | 1 | 2007 | 75 | 0.060 |
Why?
| | Secondary Prevention | 1 | 2006 | 84 | 0.060 |
Why?
| | Physician-Patient Relations | 1 | 2007 | 143 | 0.060 |
Why?
| | Drug Resistance | 1 | 2006 | 68 | 0.060 |
Why?
| | Anti-Asthmatic Agents | 2 | 2002 | 33 | 0.060 |
Why?
| | Brachial Artery | 1 | 2005 | 17 | 0.060 |
Why?
| | Polytetrafluoroethylene | 1 | 2005 | 33 | 0.060 |
Why?
| | Arm | 1 | 2005 | 47 | 0.060 |
Why?
| | Central Nervous System Stimulants | 1 | 2007 | 199 | 0.060 |
Why?
| | Radial Artery | 1 | 2005 | 34 | 0.060 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2005 | 22 | 0.060 |
Why?
| | Hemoglobin, Sickle | 1 | 2004 | 5 | 0.060 |
Why?
| | Hemoglobin SC Disease | 1 | 2004 | 5 | 0.060 |
Why?
| | Community Networks | 1 | 2005 | 50 | 0.060 |
Why?
| | Sickle Cell Trait | 1 | 2004 | 3 | 0.060 |
Why?
| | Veins | 1 | 2005 | 74 | 0.060 |
Why?
| | Blood Coagulation Factors | 1 | 2004 | 17 | 0.060 |
Why?
| | Aged | 3 | 2014 | 10142 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2004 | 111 | 0.050 |
Why?
| | Drug Utilization | 1 | 2004 | 77 | 0.050 |
Why?
| | Homeostasis | 1 | 2004 | 205 | 0.050 |
Why?
| | Hospitals, Pediatric | 1 | 2004 | 239 | 0.050 |
Why?
| | Inhalation Spacers | 1 | 2002 | 6 | 0.050 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2002 | 9 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2004 | 492 | 0.050 |
Why?
| | Pneumonia, Bacterial | 1 | 2003 | 30 | 0.050 |
Why?
| | Frail Elderly | 1 | 2002 | 37 | 0.050 |
Why?
| | Immunization | 1 | 2002 | 68 | 0.050 |
Why?
| | Homozygote | 1 | 2021 | 57 | 0.040 |
Why?
| | Male | 4 | 2014 | 26652 | 0.040 |
Why?
| | Heterozygote | 1 | 2021 | 91 | 0.040 |
Why?
| | Membrane Transport Proteins | 1 | 2021 | 46 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2002 | 77 | 0.040 |
Why?
| | Chronic Disease | 1 | 2004 | 585 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2002 | 399 | 0.040 |
Why?
| | Placenta Diseases | 1 | 2021 | 15 | 0.040 |
Why?
| | Adenosine Triphosphatases | 1 | 2021 | 91 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2004 | 1035 | 0.040 |
Why?
| | Arabidopsis Proteins | 1 | 2021 | 24 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 140 | 0.040 |
Why?
| | Fetal Blood | 1 | 2021 | 79 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2021 | 195 | 0.040 |
Why?
| | Pneumonia, Viral | 1 | 2003 | 177 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2021 | 274 | 0.040 |
Why?
| | Hospitalization | 1 | 2004 | 739 | 0.040 |
Why?
| | Smoking Cessation | 1 | 2002 | 315 | 0.040 |
Why?
| | Prognosis | 1 | 2004 | 2093 | 0.040 |
Why?
| | Adult | 3 | 2021 | 14095 | 0.040 |
Why?
| | Heart Failure | 1 | 2005 | 565 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2021 | 328 | 0.040 |
Why?
| | Time Factors | 1 | 2005 | 2970 | 0.040 |
Why?
| | Gene Expression | 1 | 2021 | 618 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2002 | 316 | 0.040 |
Why?
| | Cohort Studies | 1 | 2002 | 1541 | 0.040 |
Why?
| | Myocardial Infarction | 1 | 2002 | 445 | 0.030 |
Why?
| | Aging | 1 | 2002 | 701 | 0.030 |
Why?
| | Hospitals | 1 | 2011 | 180 | 0.020 |
Why?
| | Durable Medical Equipment | 1 | 2002 | 2 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2014 | 6610 | 0.010 |
Why?
| | Pharmacies | 1 | 2002 | 60 | 0.010 |
Why?
| | Middle Aged | 1 | 2014 | 13028 | 0.010 |
Why?
|
|
Golden's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|